Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], methotrexate, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 21
States / cities: Santa Monica, California • Upland, California • Whittier, California + 18 more

Conditions: Rheumatoid Arthritis, Osteoarthritis Shoulder, Fractures Humerus, Avascular Necrosis, Correction of Functional Deformity, Traumatic Arthritis, Revision of Other Devices if Sufficient Bone Stock Remains, Rotator Cuff Tears
Interventions: Tornier HRS (HUMERAL RECONSTRUCTION SYSTEM) shoulder system; Device
Lead sponsor: Stryker Trauma and Extremities; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 4
States / cities: Denver, Colorado • Bradenton, Florida • Tampa, Florida + 1 more

Conditions: Osteoarthritis, Rheumatoid Arthritis, Other Inflammatory Arthritis, Post-Traumatic Arthritis, Juvenile Rheumatoid Arthritis, Avascular Necrosis
Interventions: Total Knee Arthroplasty, Total knee replacement; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 3
States / cities: Greensboro, North Carolina • Austin, Texas • Lakewood, Washington

Conditions: Rheumatoid Arthritis
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Multiple Sclerosis
Interventions: other disease-modifying therapy, Fingolimod; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 3,076 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 208
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 181 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BAY86-5046_Interferon-beta-1b; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 27
States / cities: Many Locations, Alabama • Many Locations, California • Many Locations, Colorado + 24 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon beta 1b (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Diabetes, Cardiovascular Disease, Epilepsy, Migraine, Neurological Disorders, Cancer, Bariatric Surgery Candidate, Organ or Tissue Transplant; Complications, Lupus Erythematosus, Systemic, Other Hematologic Conditions, Other Venous Embolism and Thrombosis
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Sacramento, California + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 21,340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more

Conditions: Raynaud's Disease
Interventions: Topical organogel with nitroglycerin; Drug
Lead sponsor: MediQuest Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Stanford, California • Denver, Colorado • Farmington, Connecticut + 14 more

Conditions: Healthy Volunteer, Dermatologic Diseases, Systemic Diseases
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Interferon-1beta (Betaseron, BAY86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 19
States / cities: Many Locations, Alabama • Many Locations, Arizona • Many Locations, Delaware + 16 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 56
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more

Conditions: Degenerative Osteoarthritis, Post-traumatic; Arthrosis, Rheumatoid Arthritis & Other Inflammatory Polyarthropathies, Rheumatoid Arthritis of Subtalar Joint
Interventions: Subtalar Arthrodesis; Procedure
Lead sponsor: AlloSource; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 5
States / cities: Baltimore, Maryland • Grand Rapids, Michigan • Edina, Minnesota + 2 more

Conditions: Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
Interventions: topical organogel with nitroglycerin; Drug
Lead sponsor: MediQuest Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Schizo-Affective Type of Psychosis, Schizophrenia
Interventions: Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram, Ocrelizumab infusion; Behavioral · Diagnostic Test · Biological
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Arthritis, Arthritis, Degenerative, Rheumatoid Arthritis, Post-traumatic Arthrosis of Other Joints, Shoulder Region, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Fracture, Avascular Necrosis, Joint Instability, Joint Trauma, Dislocation, Shoulder, Pain, Shoulder
Interventions: Integra TITAN™ Total Shoulder Generation 1.0; Device
Lead sponsor: Smith & Nephew, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Indianapolis, Indiana • Philadelphia, Pennsylvania

Conditions: Common Variable Immunodeficiency (CVID), Primary Immune Regulatory Disorder, Immune Dysregulation, DiGeorge Syndrome, STAT 1 Gain of Function, STAT 3 Gain of Function, Hypomorphic RAG1 Deficiency, CD40 Ligand Deficiency, Mendelian Susceptibility to Mycobacterial Disease, GATA2 Associated Immunodeficiency, CD40 Deficiency, Hypomorphic RAG2 Deficiency, Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome, Omenn Syndrome, Chronic Granulomatous Disease
Interventions: Hematopoietic stem cell transplant (HSCT); Biological
Lead sponsor: Paul Szabolcs; Other
Eligibility: 5 Years to 40 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions: Specimen sample; Diagnostic Test
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
Interventions: AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more

Conditions: Adjustment Disorder
Interventions: RE104 for Injection; Drug
Lead sponsor: Reunion Neuroscience Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • San Diego, California + 28 more

Search by objective public record fields.

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Tornier HRS (Humeral Reconstruction System) Study (REVIVE)

Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA

A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

A Complex Contraception Registry

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

The Acquisition of Blood and Skin Samples From Normal Volunteers to Support Research Activities on Dermatologic Diseases

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft

Lab Study of MQX-503 in Treatment of Raynaud's

Ocrelizumab for Psychosis by Autoimmunity

Clinical Evaluation of the TITAN™ Total Shoulder System

Hematopoietic Stem Cell Transplantation (HSCT) for Common Variable Immunodeficiency (CVID) and Other Autoimmune Manifestations of Primary Immune Regulatory Disorders (PIRD)

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses